MiMedx Group Inc (MDXG) had a rough trading day for Tuesday December 10 as shares tumbled 8.22%, or a loss of $-0.6 per share, to close at $6.70. After opening the day at $7.30, shares of MiMedx Group Inc traded as high as $7.30 and as low as $6.70. Volume was 820,556 shares over 767 trades, against an average daily volume of n/a shares and a total float of 110.75 million.
As a result of the decline, MiMedx Group Inc now has a market cap of $742.05 million. In the last year, shares of MiMedx Group Inc have traded between a range of $7.50 and $1.08, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from human amniotic membrane and birth tissues and human skin and bone. Its products are primarily targeted toward the wound-care, surgical, sports medicine, and orthopedics markets. MiMedx’s key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. It also sells OrthoFlo, an allograft derived from amniotic fluid. In addition, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
MiMedx Group Inc is based out of Marietta, GA and has some 690 employees. Its CEO is Timothy R. Wright.
MiMedx Group Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.